

NOV 05 2004

TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
3613/1/US

Attaching Office Of: Stephen P. Arneric

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/727,918	December 4, 2003	TBA	26 648	1646	7539

Title: METHOD FOR THE TREATMENT, PREVENTION, OR INHIBITION OF A CNS DISORDER AND/OR
PAIN AND INFLAMMATION USING A COMBINATION OF REBOXETINE AND A CYCLOOXYGENASE-2
SELECTIVE INHIBITOR AND COMPOSITIONS THEREOF

COMMISSIONER FOR PATENTS:


Transmitted herewith is:

Postcard, Information Disclosure Statement, Form 1449, Copy of (26) Ref.

in the above identified application.

- No additional fee is required.
- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 19-1025 as described below.
- Charge the amount of _____
- Credit any overpayment.
- Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.


Signature

Dated: November 2, 2004

James Michael Warner
Registration No. 45,199
Customer No. 26 648

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

11/02/04


(Date)


Signature of Person Mailing Correspondence

Matthew J. Bell

Typed or Printed Name of Person Mailing Correspondence

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of
Stephen P. Armeric)
Serial No. 10/727,918) Attorney Docket No. 3613/1/US
Filed: December 4, 2003)
Group Art Unit: 1646
Examiner: TBA

For A METHOD FOR THE TREATMENT, PREVENTION, OR INHIBITION OF A CNS
DISORDER AND/OR PAIN AND INFLAMMATION USING A COMBINATION OF
REBOXETINE AND A CYCLOOXYGENASE-2

November 2, 2004

Commissioner of Patents
Alexandria, VA 22313


SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith various documents cited on the attached Form PTO 1449. Applicants respectfully request that the Examiner consider and enter all the documents cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

No additional fees are believed due to ensure consideration of the attached documents by the Examiner. However, if any additional fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

Respectfully submitted,


James M. Warner, Reg. No. 45,199
Attorney for Applicants
(314) 274-3642

Pharmacia Corporation of Pfizer
Corporate Patent Department
P.O. Box 1027
St. Louis, MO 63006



Sheet 1 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 3613/1/US	APPLICATION NO.: 10/727,918
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				INVENTOR: Stephen P. Arneric	
(Use several sheets if necessary)				Filed: : 12/04/2003	Group: 1646

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
1	5,434,178	06/18/95	Talley, et al.	514	406	11/30/93
2	5,476,944	12/19/95	Partis, et al.	514	357	05/19/94
3	5,643,933	07/01/97	Talley, et al.	514	372	06/2/95
4	5,859,257	01/12/99	Talley, et al.	548	247	08/14/96
5	5,932,598	08/03/99	Talley, et al.	514	341	01/12/98
6	6,156,781	12/05/00	Talley, et al.	514	406	11/24/99
7	6,110,960	08/29/00	Janusz, et al.	514	432	06/06/97
8	6,180,651 B1	01/30/01	Nicolai	514	336	09/19/98
9	5,521,207	05/28/96	Graneto	514	406	04/06/94
10	5,760,068	01/02/98	Talley, et al.	514	403	06/08/95
11	2001/0029257	10/11/01	Murdock	514	220	10/11/01
12	4,229,449	10/21/80	Melloni, et al.	424	248.58	01/08/79
13	6,465,458 B1	10/15/02	Wong, et al.	514	239	06/22/00
14	6,290,986 B1	09/18/01	Murdock, et al.	424	449	06/29/98
15	6,229,010 B1	05/08/01	Crocker, et al.	544	132	12/09/98
16	6,096,742 B1	08/01/00	Crocker, et al.	514	241	12/15/98
17	6,117,855	09/12/00	Carison, et al.	514	90	10/17/98
18	6,066,643	05/23/00	Perry	514	239	09/17/98
19	6,028,070	02/02/00	Heiligenstein	514	238.8	09/17/98
20	6,046,193	04/04/00	Heiligenstein	514	239	09/17/98
21	6,034,256	05/07/00	Carter, et al.	549	456	04/17/98

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
22	WO 00/24719	05/04/00	Black, et al.	237	14	10/27/99
23	WO 002/102297	12/27/02	Muller, et al.	A61K	-----	05/31/02
24	WO 0101973	01/11/01	Wong, Eric, H.F.	31	00	06/22/04
25	WO 0115687	03/08/01	Stoner, et al.	31	18	12/24/00
26	WO 9847890	10/30/03	Stephenson, et al.	31	35	04/14/03
27	WO 9911605	03/11/99	Novartis-Efffindungen, et al.	229	42	08/26/97
28	WO 03088958	10/29/98	Carter, et al.	311	58	04/18/98
29	WO 0162236	08/30/01	Rogosky, et al.	31	00	01/23/01

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Sheet 2 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 3613/1/US	APPLICATION NO.: 10/727,918
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		INVENTOR: Stephen P. Arneric	
(Use several sheets if necessary)		Filed: 12/04/2003	Group: 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial	
30	Needleman, P., et al., <i>J. Rheumatol.</i> , 24, Suppl. 49:6 – 8 (1997).
31	Fu, J. Y., et al., <i>J. Biol. Chem.</i> , 265(28): 16737-40 (1990).
32	Samad, T. A., et al., <i>Nature</i> , 410(6827):471-5 (2001).
33	Buttgereit, F., et al., <i>Am. J. Med.</i> , 110(3 Suppl. 1):13-9 (2001).
34	Osiri, M., et al., <i>Mayo Clin. Proc.</i> , 75(10):1027-38 (2000).
35	Wollheim, F.A., <i>Current Opin. Rheumatol.</i> , 13:193-201 (2001).
36	Hillson, J. L., et al., <i>Expert Opin Pharmacother.</i> , 1(5):1053-66 (2000).
37	Everts, B., et al., <i>Clin. Rheumatol.</i> , 19(5):331-43 (2000).
38	Jamali, F., <i>J. Pharm. Pharm. Sci.</i> , 4(1):1-6 (2001).
39	Saag, K., et al., <i>Arch. Fam. Med.</i> , 9(10):1124-34 (2000).
40	Yoshimi, N., et al., in <i>Japanese J. Cancer Res.</i> , 90(4):406-412 (1999).
41	Iwata, K., et al., in <i>Jpn. J. Pharmacol.</i> , 75(2):191-194 (1997).
42	The Pharmacologist Basis of Therapeutics, Ninth Edition (1996), Appendix II, pp. 1707-1711.
43	Winter, et al., (Proc. Soc. Exp. Biol. Med., 111, 544 (1962)).
44	Otterness and Bliven, Laboratory Models for Testing NSAIDS, in <i>Non-steroidal Anti-Inflammatory Drugs</i> , (J. Lombardino, ed. (1985)).
45	Hargreaves, et al., (<i>Pain</i> , 32, 77 (1988)).
46	J. Stuart, <i>Annual Rev. Immunol.</i> , 2, 199 (1984).
47	P. Wooley, et al., trans. Proc., 15, 180 (1983).
48	R. Jonsson, <i>J. Immunol. Methods</i> , 88, 109 (1986).

1

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)